RxPG News Feed for RxPG News

Medical Research Health Special Topics World
  Home
 
   Health
 Aging
 Asian Health
 Events
 Fitness
 Food & Nutrition
 Happiness
 Men's Health
 Mental Health
 Occupational Health
 Parenting
 Public Health
 Sleep Hygiene
 Women's Health
 
   Healthcare
 Africa
 Australia
 Canada Healthcare
 China Healthcare
 India Healthcare
 New Zealand
 South Africa
 UK
 USA
 World Healthcare
 
   Latest Research
 Aging
 Alternative Medicine
 Anaethesia
 Biochemistry
 Biotechnology
 Cancer
 Cardiology
 Clinical Trials
 Cytology
 Dental
 Dermatology
 Embryology
 Endocrinology
 ENT
 Environment
 Epidemiology
 Gastroenterology
 Genetics
 Gynaecology
 Haematology
 Immunology
 Infectious Diseases
 Medicine
 Metabolism
 Microbiology
 Musculoskeletal
 Nephrology
 Neurosciences
 Obstetrics
 Ophthalmology
 Orthopedics
 Paediatrics
 Pathology
 Pharmacology
 Physiology
 Physiotherapy
 Psychiatry
  Anorexia Nervosa
  Anxiety
  Bulimia
  CFS
  Child Psychiatry
  Depression
   Antidepressants
  Forensic Psychiatry
  Learning-Disabilities
  Mood Disorders
  Neuropsychiatry
  Peri-Natal Psychiatry
  Personality Disorders
  Psychology
  Psychoses
  Psychotherapy
  Sleep Disorders
  Substance Abuse
  Suicide
 Radiology
 Rheumatology
 Sports Medicine
 Surgery
 Toxicology
 Urology
 
   Medical News
 Awards & Prizes
 Epidemics
 Launch
 Opinion
 Professionals
 
   Special Topics
 Ethics
 Euthanasia
 Evolution
 Feature
 Odd Medical News
 Climate

Last Updated: Oct 11, 2012 - 10:22:56 PM
Research Article
Depression Channel

subscribe to Depression newsletter
Latest Research : Psychiatry : Depression

   EMAIL   |   PRINT
Cost effectiveness of Combination Therapies in Severe Depression

Dec 1, 2006 - 3:24:40 PM , Reviewed by: Venkat Yelamanchili
Targeting combination therapy on severe forms of depression could be a more efficient way of using limited resources, say the researchers.

 
[RxPG] Psychological therapy and antidepressants given together (combination therapy) is likely to be a cost-effective treatment for severe depression, according to a new study.

But the cost-effectiveness of combination therapy for moderate depression is more uncertain.

The study, published in the December issue of the British Journal of Psychiatry, took the form of a decision analysis developed for the National Institute of Clinical Excellence (NICE, 2004) depression guideline to evaluate the likely costs and outcomes of the first-line use of antidepressant medication, or combination therapy, for moderate and severe depression in secondary care in the UK (National Collaborating Centre for Mental Health, 2005).

Systematic literature reviews were carried out to identify clinical, utility and cost data. A ‘decision analytic model’ was then developed to compare the effectiveness and costs of using antidepressant therapy alone with combination therapy for people with moderate and severe depression over a 3-month initial treatment period and 12-month follow-up.

The researchers chose cognitive behavioural therapy for their analysis, as it has a relatively large, high-quality evidence base compared with other psychological therapies provided by the NHS.

The antidepressant therapy consisted of 3 months of daily 40g fluoxetine, with an average of four specialist visits, assuming two visits by a consultant and two visits by a specialist registrar.

Combination therapy involved the use of this antidepressant treatment protocol and cognitive-behavioural therapy for 3 months. A full course included 16 sessions of about 50 minutes.

It was found that over the 15-month analysis period, combination therapy resulted in higher costs and an expected 0.16 increase per person in the probability of remission and no relapse, compared with antidepressants.

The cost per additional successfully treated patient was £4056. The cost per quality-adjusted life year gained was £5777 for severe depression, and £14,540 for moderate depression.

The results indicate that targeting combination therapy on severe forms of depression could be a more efficient way of using limited resources, say the researchers.

They comment that the cost results suggest that although the initial treatment cost of combination therapy is substantially higher, these costs are in part offset by savings from lower treatment costs in the subsequent year.

Based on this evidence, the NICE guideline for depression (2004) recommends combination therapy for severe depression and antidepressant therapy for moderate depression, with combination therapy as a second-line intervention.

Considering the importance of patient preference, recommendations are also made about the use of psychological interventions where patients declined antidepressant medication alone, or had previously not responded to it.

The consequent increase in the need for psychological treatments is likely to require additional resources in the NHS, mostly the cost and time implications of extra staff training and employment. These are currently under consideration by NICE and the NHS in England and Wales.



Publication: Royal College of Psychiatrists
On the web: www.rcpsych.ac.uk 

Advertise in this space for $10 per month. Contact us today.


Related Depression News
Does Dad's stress affect his unborn children?
Unhealthy eating leads to increased depression
Online CBT is Effective in Depression & Panic Disorders: RCT
Care Management Reduces Suicidal Ideation in Geriatric Depression
Incubator care at birth reduces depression risk in adult life
Depression during pregnancy doubles risk of premature delivery
Depression is wrongly seen as natural part of getting older
Depression increases risk of Alzheimer's disease
Antidepressants that are more efficient and faster
Depressed older people risk losing their minds

Subscribe to Depression Newsletter

Enter your email address:


 Additional information about the news article
References:
Simon J, Pilling S, Burbeck R and Goldberg D (2006) Treatment options in moderate and severe depression: decision analysis supporting a clinical guideline, British Journal of Psychiatry, 189, 494-501.

 Feedback
For any corrections of factual information, to contact the editors or to send any medical news or health news press releases, use feedback form

Top of Page

 
Contact us

RxPG Online

Nerve

 

    Full Text RSS

© All rights reserved by RxPG Medical Solutions Private Limited (India)